CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -22.25% | 25.85% | 5.88% | -22.71% | 48.96% |
| Total Depreciation and Amortization | -0.98% | -0.90% | -23.71% | 27.70% | -4.65% |
| Total Amortization of Deferred Charges | -13.21% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 134.98% | -75.22% | 157.37% | 51.00% | -93.93% |
| Change in Net Operating Assets | 158.11% | 76.00% | -168.07% | 107.51% | 166.07% |
| Cash from Operations | -7.41% | 23.32% | -17.66% | -9.36% | 25.68% |
| Capital Expenditure | 36.11% | -28.57% | 2.51% | -598.65% | 36.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 75.15% | 86.59% | -1,187.71% | 131.65% | -269.99% |
| Cash from Investing | 74.69% | 86.45% | -1,204.18% | 131.20% | -270.38% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -46.35% | 34.82% | -94.71% | -60.77% | 13,042.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 92.13% | -- | -- | -- |
| Cash from Financing | -37.97% | -98.79% | 408.45% | -60.77% | 13,042.87% |
| Foreign Exchange rate Adjustments | 0.00% | 118.75% | -3,300.00% | 103.70% | -133.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.75% | -282.69% | 18.30% | -34.26% | 323.45% |